Advertisement
CRDL vs CRON
To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CRDL is a Hold and CRON is a StrongBuy.
CRDL's RSI Oscillator is remaining in oversold zone for 15 days
The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an uptrend is expected.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +6.36% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRDL advanced for three days, in 178 of 220 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.
CRDL may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
CRDL moved below its 50-day moving average on September 28, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for CRDL crossed bearishly below the 50-day moving average on October 02, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 15 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 88%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRDL declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 88%.
The Aroon Indicator for CRDL entered a downward trend on October 22, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 32 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 61 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.815) is normal, around the industry mean (10.407). P/E Ratio (-3.382) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (178.797).
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. CRDL’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 100 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRDL’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
CRON in upward trend: price rose above 50-day moving average on October 20, 2026
CRON moved above its 50-day moving average on October 20, 2026 date and that indicates a change from a downward trend to an upward trend. In 61 of 71 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 86%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 21, 2026. You may want to consider a long position or call options on CRON as a result. In 81 of 106 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.
The Moving Average Convergence Divergence (MACD) for CRON just turned positive on October 21, 2026. Looking at past instances where CRON's MACD turned positive, the stock continued to rise in 47 of 59 cases over the following month. The odds of a continued upward trend are 80%.
Following a +5.03% 3-day Advance, the price is estimated to grow further. Considering data from situations where CRON advanced for three days, in 168 of 229 cases, the price rose further within the following month. The odds of a continued upward trend are 73%.
Bearish Trend Analysis
The RSI Indicator demonstrated that the stock has entered the overbought zone. This may point to a price pull-back soon.
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
The 10-day moving average for CRON crossed bearishly below the 50-day moving average on October 13, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 19 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 84%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRON declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 76%.
CRON broke above its upper Bollinger Band on October 21, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 39 (best 1 - 100 worst), indicating steady price growth. CRON’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 52 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.188) is normal, around the industry mean (10.407). P/E Ratio (18.132) is within average values for comparable stocks, (-6.173). Projected Growth (PEG Ratio) (0.020) is also within normal values, averaging (2.152). Dividend Yield (0.000) settles around the average of (0.037) among similar stocks. P/S Ratio (6.993) is also within normal values, averaging (178.797).
The Tickeron SMR rating for this company is 80 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 93 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. CRON’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock worse than average.
CRDL | CRON | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 53 | 29 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 61 Fair valued | 52 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 100 | 80 | |
PRICE GROWTH RATING 1..100 | 79 | 39 | |
P/E GROWTH RATING 1..100 | 32 | 93 | |
SEASONALITY SCORE 1..100 | 85 | n/a |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
CRON's Valuation (52) in the Pharmaceuticals Other industry is in the same range as CRDL (61) in the null industry. This means that CRON’s stock grew similarly to CRDL’s over the last 12 months.
CRON's Profit vs Risk Rating (100) in the Pharmaceuticals Other industry is in the same range as CRDL (100) in the null industry. This means that CRON’s stock grew similarly to CRDL’s over the last 12 months.
CRON's SMR Rating (80) in the Pharmaceuticals Other industry is in the same range as CRDL (100) in the null industry. This means that CRON’s stock grew similarly to CRDL’s over the last 12 months.
CRON's Price Growth Rating (39) in the Pharmaceuticals Other industry is somewhat better than the same rating for CRDL (79) in the null industry. This means that CRON’s stock grew somewhat faster than CRDL’s over the last 12 months.
CRDL's P/E Growth Rating (32) in the null industry is somewhat better than the same rating for CRON (93) in the Pharmaceuticals Other industry. This means that CRDL’s stock grew somewhat faster than CRON’s over the last 12 months.
| CRDL | CRON | |
|---|---|---|
| RSI ODDS (%) | 1 day ago 90% | 1 day ago 78% |
| Stochastic ODDS (%) | N/A | 1 day ago 82% |
| Momentum ODDS (%) | N/A | 1 day ago 76% |
| MACD ODDS (%) | N/A | 1 day ago 80% |
| TrendWeek ODDS (%) | 1 day ago 85% | 1 day ago 78% |
| TrendMonth ODDS (%) | 1 day ago 90% | 1 day ago 77% |
| Advances ODDS (%) | 2 days ago 81% | 1 day ago 73% |
| Declines ODDS (%) | 11 days ago 88% | 9 days ago 76% |
| BollingerBands ODDS (%) | 1 day ago 88% | 1 day ago 82% |
| Aroon ODDS (%) | 1 day ago 90% | N/A |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
CRDL’s FA Score shows that 1 FA rating(s) are green while CRON’s FA Score has 0 green FA rating(s).
- CRDL’s FA Score: 1 green, 4 red.
- CRON’s FA Score: 0 green, 5 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
CRDL’s TA Score shows that 3 TA indicator(s) are bullish while CRON’s TA Score has 5 bullish TA indicator(s).
- CRDL’s TA Score: 3 bullish, 4 bearish.
- CRON’s TA Score: 5 bullish, 3 bearish.
Price Growth
CRDL (@Pharmaceuticals: Generic) experienced а +2.63% price change this week, while CRON (@Pharmaceuticals: Generic) price change was +7.28% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -2.94%. For the same industry, the average monthly price growth was -9.84%, and the average quarterly price growth was +9.53%.
Reported Earning Dates
CRDL is expected to report earnings on Nov 12, 2026.
CRON is expected to report earnings on Nov 05, 2026.
Industries' Descriptions
@Pharmaceuticals: Generic (-2.94% weekly)A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.
Advertisement
CRDL and
Correlation & Price change
A.I.dvisor tells us that CRDL and SNOA have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that CRDL and SNOA's prices will move in lockstep.
| Ticker / NAME | Correlation To CRDL | 1D Price Change % | ||
|---|---|---|---|---|
| CRDL | 100% | -1.71% | ||
| SNOA - CRDL | 29% Poorly correlated | N/A | ||
| LNTH - CRDL | 27% Poorly correlated | -0.14% | ||
| CRON - CRDL | 25% Poorly correlated | +1.62% | ||
| SCYX - CRDL | 24% Poorly correlated | +0.66% | ||
| SNDL - CRDL | 23% Poorly correlated | +0.78% | ||
More | ||||
CRON and
Correlation & Price change
A.I.dvisor indicates that over the last year, CRON has been closely correlated with SNDL. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if CRON jumps, then SNDL could also see price increases.
| Ticker / NAME | Correlation To CRON | 1D Price Change % | ||
|---|---|---|---|---|
| CRON | 100% | +1.62% | ||
| SNDL - CRON | 73% Closely correlated | +0.78% | ||
| ACB - CRON | 59% Loosely correlated | +0.25% | ||
| TLRY - CRON | 58% Loosely correlated | +0.34% | ||
| CGC - CRON | 58% Loosely correlated | -1.00% | ||
| TRLV - CRON | 55% Loosely correlated | -0.73% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| IBDW | 20.26 | 0.13 | +0.65% |
| iShares iBonds Dec 2031 Term Corporate ETF (IBDW) | |||
| PMMR | 27.53 | N/A | N/A |
| PGIM S&P 500 Max Buffer ETF March (PMMR) | |||
| NUEM | 39.01 | -1.28 | -3.17% |
| Nuveen ESG Emerging Markets Equity ETF (NUEM) | |||
| IPO | 48.16 | -2.23 | -4.43% |
| Renaissance IPO ETF (IPO) | |||
| MARO | 2.45 | -0.17 | -6.49% |
| Yieldmax Mara Option Income Strategy ETF | |||